Xeris Biopharma Reports Second Quarter 2024 Financial Results
Xeris Biopharma Holdings, Inc. (XERS)
Last xeris biopharma holdings, inc. earnings: 3/11 06:00 am
Check Earnings Report
Company Research
Source: Business Wire
Achieved revenue of $48.1M including record product revenue of $46.5MTotal revenues increased 18% over the prior quarter and 26% over the same period prior yearEnded Q2 with $77.6M in cash, cash equivalents and short-term investmentsTightens full-year 2024 guidance: total net revenue to $190M-$200M and year-end cash balance to $60M-$75MJohn Shannon appointed CEO and Kevin McCulloch promoted to President and COO per the Company’s long-standing succession planHosting conference call and webcast today at 8:30 a.m. ET CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the second quarter and six months ended June 30, 2024 and recent corporate events.“I am very pleased to report that we posted an outstanding quarter of $48 million in total revenue, which included record
Show less
Read more
Impact Snapshot
Event Time:
XERS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XERS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XERS alerts
High impacting Xeris Biopharma Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
XERS
News
- Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last? [Yahoo! Finance]Yahoo! Finance
- Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) most popular amongst individual investors who own 53% of the shares, institutions hold 43% [Yahoo! Finance]Yahoo! Finance
- Xeris to Participate in Upcoming Investor ConferencesBusiness Wire
- Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- Xeris Biopharma: Q2 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
XERS
Earnings
- 8/8/24 - Beat
XERS
Analyst Actions
- 8/15/24 - HC Wainwright
XERS
Sec Filings
- 8/13/24 - Form 4
- 8/12/24 - Form 4
- 8/9/24 - Form 4
- XERS's page on the SEC website